Characterizing tumor invasiveness of glioblastoma using multiparametric magnetic resonance imaging.

MRI diffusion tensor imaging glioblastoma magnetic resonance spectroscopy oncology perfusion imaging prognosis

Journal

Journal of neurosurgery
ISSN: 1933-0693
Titre abrégé: J Neurosurg
Pays: United States
ID NLM: 0253357

Informations de publication

Date de publication:
26 Apr 2019
Historique:
received: 22 10 2018
accepted: 26 12 2018
pubmed: 27 4 2019
medline: 27 4 2019
entrez: 27 4 2019
Statut: epublish

Résumé

The objective of this study was to characterize the abnormalities revealed by diffusion tensor imaging (DTI) using MR spectroscopy (MRS) and perfusion imaging, and to evaluate the prognostic value of a proposed quantitative measure of tumor invasiveness by combining contrast-enhancing (CE) and DTI abnormalities in patients with glioblastoma. Eighty-four patients with glioblastoma were recruited preoperatively. DTI was decomposed into isotropic (p) and anisotropic (q) components. The relative cerebral blood volume (rCBV) was calculated from the dynamic susceptibility contrast imaging. Values of N-acetylaspartate, myoinositol, choline (Cho), lactate (Lac), and glutamate + glutamine (Glx) were measured from multivoxel MRS and normalized as ratios to creatine (Cr). Tumor regions of interest (ROIs) were manually segmented from the CE T1-weighted (CE-ROI) and DTI-q (q-ROI) maps. Perfusion and metabolic characteristics of these ROIs were measured and compared. The relative invasiveness coefficient (RIC) was calculated as a ratio of the characteristic radii of CE-ROI and q-ROI. The prognostic significance of RIC was tested using Kaplan-Meier and multivariate Cox regression analyses. The Cho/Cr, Lac/Cr, and Glx/Cr in q-ROI were significantly higher than CE-ROI (p = 0.004, p = 0.005, and p = 0.007, respectively). CE-ROI had significantly higher rCBV values than q-ROI (p < 0.001). A higher RIC was associated with worse survival in a multivariate overall survival (OS) model (hazard ratio [HR] 1.40, 95% confidence interval [CI] 1.06-1.85, p = 0.016) and progression-free survival (PFS) model (HR 1.55, 95% CI 1.16-2.07, p = 0.003). An RIC cutoff value of 0.89 significantly predicted shorter OS (median 384 vs 605 days, p = 0.002) and PFS (median 244 vs 406 days, p = 0.001). DTI-q abnormalities displayed higher tumor load and hypoxic signatures compared with CE abnormalities, whereas CE regions potentially represented the tumor proliferation edge. Integrating the extents of invasion visualized by DTI-q and CE images into clinical practice may lead to improved treatment efficacy.

Identifiants

pubmed: 31026822
doi: 10.3171/2018.12.JNS182926
pii: 2018.12.JNS182926
doi:
pii:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1465-1472

Subventions

Organisme : Department of Health
ID : NIHR/CS/009/011
Pays : United Kingdom

Auteurs

Chao Li (C)

1Cambridge Brain Tumor Imaging Laboratory, Division of Neurosurgery, Department of Clinical Neurosciences.
2Department of Neurosurgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Shuo Wang (S)

3Department of Radiology.

Jiun-Lin Yan (JL)

1Cambridge Brain Tumor Imaging Laboratory, Division of Neurosurgery, Department of Clinical Neurosciences.
4Department of Neurosurgery, Chang Gung Memorial Hospital, Keelung, Taiwan.
5Chang Gung University College of Medicine, Taoyuan, Taiwan.

Turid Torheim (T)

6Cancer Research UK Cambridge Institute, and.
7CRUK & EPSRC Cancer Imaging Centre in Cambridge and Manchester, Cambridge.

Natalie R Boonzaier (NR)

1Cambridge Brain Tumor Imaging Laboratory, Division of Neurosurgery, Department of Clinical Neurosciences.
8Developmental Imaging and Biophysics Section, Great Ormond Street Institute of Child Health, University College London; and.

Rohitashwa Sinha (R)

1Cambridge Brain Tumor Imaging Laboratory, Division of Neurosurgery, Department of Clinical Neurosciences.

Tomasz Matys (T)

3Department of Radiology.
9Cancer Trials Unit, Department of Oncology, Addenbrooke's Hospital, Cambridge, United Kingdom.

Florian Markowetz (F)

6Cancer Research UK Cambridge Institute, and.
7CRUK & EPSRC Cancer Imaging Centre in Cambridge and Manchester, Cambridge.

Stephen J Price (SJ)

1Cambridge Brain Tumor Imaging Laboratory, Division of Neurosurgery, Department of Clinical Neurosciences.
10Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, United Kingdom.

Classifications MeSH